Gene Editing
Maturity
4 / 5
Basis, source, vintage
Approved therapies in market; agricultural applications advancing; delivery, cost and governance are the binding constraints.
Source: Regulatory approval records for CRISPR-based therapies (2024–2026)
What it is
Making targeted changes to a genome — CRISPR and its successors — in medicine, agriculture and industrial biology.
What it does
It moves biology from reading to writing. The first approved therapies exist, which makes this one of the few frontier technologies in this Compendium with a delivered clinical outcome.
Common misconception
That the constraint is technical. Delivery to the right cells, cost per patient, and the governance of heritable edits are each further from resolution than the editing itself.
Steepens
- Longevity and the Healthspan Gap — large
- Food System Transformation — moderate
- Zoonotic and Antimicrobial Resistance Risk — moderate
- Biodiversity Loss — marginal · marginal: not counted in the minimum
What would change its gradient
- In-vivo delivery, the central technical problem
- Cost per patient, which decides reach
- International governance of heritable editing, currently national and uneven
Shares megatrends with
- BioTech & Genomics
- Vaccine Platforms & Antimicrobials
- AgTech
- Alternative Proteins & Precision Fermentation
- Marine & Ocean Technology
- Sensors & Earth Observation
In the book
Why the Future Arrives Unevenly — Ch. 7 — The Inversion of the Population Pyramid · Ch. 12 — Reading the Ramp · Ch. 14 — How Hype Is Manufactured
Sources
- Approved therapies in market; agricultural applications advancing; delivery, cost and governance are the binding constraints. Source: Regulatory approval records for CRISPR-based therapies (2024–2026).